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Abstract
Heart failure (HF) with either reduced or preserved ejection fraction is an increasingly prevalent condition. Cardiac imaging plays
a central role in trying to identify the underlying cause of the underlying systolic and diastolic dysfunction, as the imaging
findings have implications for patient’s management and individualised treatment. The imaging modalities used more frequently
in patients with heart failure in clinical routine are echocardiography and cardiac magnetic resonance. Both techniques keep some
strengths and weakness due to their spatia
l and temporal resolution. Notably, several features in the diagnostic algorithm of heart failure with preserved systolic function
(HFpEF) may be improved by an integrated approach. This review focuses on the role of each modality in characterising cardiac
anatomy, systolic and diastolic function as well as myocardial tissue characterisation in the most common phenotypes of dilated
and hypertrophied hearts.
Keywords Echocardiography . Cardiac magnetic resonance imaging . Ischemic and non-ischemic heart failure . Systolic and
diastolic dysfunction
Cardiac imaging plays a central role in trying to phenotype the
underlying cause of heart failure (HF) which has implications
for patient’s management and individualised treatment. Heart
failure has recently been classified as heart failure with re-
duced ejection fraction (HFrEF) or preserved ejection fraction
(HFpEF) [1]; although, it is still debated whether these are two
different entities or just a different stage of same ongoing
process [2, 3]. The clinical imaging modalities available to
investigate patients with heart failure are echocardiography,
nuclear cardiology techniques, computed tomography and
cardiac magnetic resonance (CMR). In this paper, we review
the role of echocardiography and CMR in patients with
HFrEF and HFpEF.
Two-dimensional transthoracic echocardiography is the
first line imaging tool providing information on function, cav-
ity size, relative wall thickness (RWT) and myocardial mass
which are used for classification of typical geometric
phenotypes—concentric or eccentric hypertrophy and remod-
elling [4, 5]. Moreover, echocardiography deformation imag-
ing can discriminate between active myocardial segmental
deformation and passive displacement of a dysfunctional
myocardial segment due to adjacent segment tethering and
global cardiac motion. However, echocardiography alone can-
not identify interstitial infiltration and intracellular accumula-
tion of metabolic substrates [6].
Cardiac magnetic resonance (CMR) is the gold standard for
cardiac anatomical and functional quantification, with unique
capabilities of non-invasive tissue characterisation [7–9],
complementing well echocardiography. Cine imaging cover-
ing the LV in short axis from apex to base is used for measur-
ing left ventricular (LV) volumes, ejection fraction (EF) and
regional function. The 3D dataset is not affected by geometric
assumptions and therefore less prone to error compared with
two-dimensional (2D) echocardiography particularly in
remodelled ventricles [10]. Non-invasive tissue characterisa-
tion by CMR can be achieved with T2 imaging and T1
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imaging post-contrast injection. The latter technique, called
late gadolinium enhancement (LGE), relies on gadolinium-
based contrast agents temporarily accumulating in regions of
increased extracellular space (due to myocardial scar, necro-
sis, fibrosis, infiltration), following the underlying pathophys-
iological process, and creating typical LGE patterns [11] that
guide the diagnosis.
Novel CMR tissue characterisation techniques are called
CMR relaxometry (T1 and T2 mapping and extracellular vol-
ume fraction (ECV)) which allow a more detailed and quan-
titative approach to tissue characterisation and 4D-Flowwhich
provides quantitative information on intracavitary flows.
Current applications appear particularly useful for diastolic
dysfunction detection although they deserve a specific com-
parison with traditional Doppler and Tissue Doppler analysis
in order to confirm the applicability in clinical practice.
The most common cardiomyopathic processes underpin-
ning HFpEF (hypertrophied phenotypes) and HFrEF (dilated
phenotypes) are discussed below.
Left ventricular hypertrophic phenotypes
Left ventricular (LV) hypertrophy (LVH) is a consequence of
an underlying genetic or acquired condition and it is accom-
panied by alterations in cardiac function and haemodynamics.
The differential diagnosis between LVH due to physiological
adaptation or underlying pathology can be challenging.
Non-physiological left ventricular hypertrophy (LVH) re-
gardless to the underlying cause leads to important cardiovas-
cular complications such as atrial fibrillation, diastolic and
systolic heart failure [12], and it is associated with increased
risk for all-cause morbidity and mortality [13].
Hypertensive heart disease
Systemic blood pressure elevation is the most common cause
of the increment in ventricular mass with a high RWT, which
results in concentric or eccentric hypertrophy and concentric
remodelling [14]. These structural changes provide a mecha-
nism for maintenance of normal LV systolic wall stress in the
presence of a high systolic pressure, although up to 60% of the
variance of LV mass may be due to genetic factors indepen-
dent of blood pressure [15]. The earliest change appears to be
an increase in RWT before there is a detectable increase in LV
mass [16]. In hypertensive heart disease (HHD), the wall
thickening is influenced by ethnicity, neurohumoral factors
and genetic variants, is commonly symmetrical and in basal
segments rarely exceeding 15 mm [17]. However, locally in-
creased wall stress in the basal septum can result in regionally
increased wall thickness—also known as septal bulging, mim-
icking other asymmetric hypertrophic phenotypes. Clinical
heart failure in hypertensive heart disease can occur either in
the set t ing of reduced or preserved LVEF [18] .
Echocardiography is the first line diagnostic tool. However,
traditional parameters offer little clue about the underlying
aetiology, hence novel applications are gaining in popularity.
Despite that cardiac hypertrophy may be analysed with the
two methods, there is an existing gap in LV hypertrophy and
mass measurement between the two techniques: indeed LV
mass is currently calculated with standardised formulas in a
parasternal longitudinal view axis in echo by the assumption
that LV has an ellipsoid shape [19]. Conversely, LV mass in
CMR is measured in a transversal view by the sum of the
whole myocardial slices from basal to apical level [20]. This
make CMR much more reproducible without geometric as-
sumption and lower cut-off value compared with echo. This is
an important item when physicians calculate the global CV
risk in hypertensive or high-risk subjects.
Global longitudinal strain (GLS) is an emerging parameter
currently available with both methods. GLS is typically re-
duced in advanced stages of HHD, and it is strongly associated
with diastolic dysfunction, it is less dependent on afterload
changes and degree of LVH compared with EF, and it has a
role in differentiating HHD from other hypertrophic pheno-
types [21, 22]. CMR is superior to echocardiography due to
its possibility of tissue characterisation. By magnetic resonance
study, it is possible to ascertain the burden of myocardial fibro-
sis, extracellular collagen deposition extension and site.
Therefore, the absence of LGE on CMR increases the predic-
tive power in diagnosing HHD over and above geometrical and
morphological features [23, 24]. Finally, HHD is normally ac-
companied with structural or functional changes in arteries or
end organs (heart, blood vessels, brain, eyes and kidney) as a
consequence of long lasting hypertension even in asymptomat-
ic patients [25]. Evidence of increased blood pressure is the
clinical hallmark of the disease, even though approximately
15% of patients might present with a normal office BP (masked
hypertension) [26]. The most common functional feature of
HHD, apart structural LVH and remodelling, is the alteration
of left filling pressure due to both increased LV mass and stiff-
ness associated with reduced elastic properties of myocardial
tissue. Notably, echocardiography and Doppler application due
to its high temporal resolution, offers a suitable and practical
tool to recognise LV diastolic filling dysfunction by the com-
bined analysis of trans-mitral pulsed waves Doppler and myo-
cardial tissue Doppler (TDI). Therefore, additional study of
pulmonary vein flow allows to a characterisation of diastolic
degree and haemodynamic conditions into the left cardiac
chamber [27, 28]. A similar analysis have recently been
reproduced during CMR examination in a phase-contrast ac-
quisition measuring trans-mitral and venous flow velocities in a
post-processing analysis including around 40 cardiac phases of
the whole cardiac cycle. Additional analysis comprises myo-
cardial tagging that calculates radial and circumferential motion
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during cardiac relaxation, and more recently, feature tracking to
detect myocardial strain [29].
LV hypertrophy in cardiac amyloidosis
Infiltrative myocardial disease particularly cardiac amyloidosis
can present with very heterogenous hypertrophic phenotypes
with wide ranges of wall thicknesses including normal [30].
Granular appearance on echocardiography, biventricular hyper-
trophy with involvement of the right ventricular free wall, in-
creased thickness of the atrio-ventricular valves, thickening of
the interatrial septum and the presence of a small pericardial
effusion usually trigger a suspicion [30]. Whereas the light
chain amyloidosis (AL) normally follows concentric symmetric
hypertrophic pattern, the transthyretin amyloidosis (TTR) is
typically asymmetrical [31]. Thickened myocardium and con-
ventional echo parameters have low accuracy for the diagnosis
of cardiac amyloidosis, which is mostly due to their low sensi-
tivity [32]. However, some echo indices, enlarged left atrial
volume index, reduced LV diameters and volumes, global pa-
rietal thickness and increased parietal backscatter have higher
specificity and have a potential to be used to ‘rule in’ potential
amyloidosis cases [33, 34], suggesting diastolic dysfunction as
a leading functional abnormality in this population. A typical
restrictive filling Doppler pattern is characterised by a high
early wave with shortened deceleration time and isovolumetric
time. Conversely, the atrial contribution is reduced and often
blunted even in those patients without atrial fibrillation.
Pulmonary flow analysis demonstrates increased atrial reverse
wave associated with both reduced systolic and diastolic waves
[35]. The alteration of intrinsic myocardial relaxation forces is
demonstrated by significative lowering of tissue e′ velocity as-
sociated with increased E/e′ ratio. Myocardial deformation pa-
rameters or patterns of regional strain values such as relative
apical sparing or septal apical-base longitudinal strain gradient
may have a better differentiating capacity in detecting and dif-
ferentiating cardiac amyloidosis from other hypertrophic sub-
strates, including HCM, hypertrophy in aortic stenosis or met-
abolic cardiomyopathies [36]. Using deformation imaging, LV
dysfunction can be detected prior to any signs of morphological
or functional impairment as assessed by 2D echocardiography
or assessment of diastolic function [34]. However, all afore-
mentioned conditions may present with regional impairment
patterns that closely resemble cardiac amyloidosis. CMR is
superior to echocardiography and plays an important role in
diagnosis of cardiac amyloidosis due to peculiar myocardial
and blood-pool gadolinium kinetics in this disease. Detection
of transmural or subendocardial LGE with suboptimal myocar-
dial nulling caused by similar myocardial and blood T1 signals,
is unusual but highly specific pattern in amyloidosis.
Furthermore, native T1 mapping values and ECVare severely
increased in amyloidosis [37]. These novel CMR parameters
are more sensitive for detecting early disease than LGE
imaging, correlate better with markers of systolic and diastolic
dysfunction and have a potential to give information on cardiac
amyloid load without usage of contrast agents [38].
Left ventricular dilated phenotypes
Dilated phenotypes are a heterogenous group characterised by
large LV cavities with eccentric remodelling or hypertrophy
and impaired contractility. Such phenotypes can be a response
to abnormal loading conditions typically in valvular disease or
hypertension, severe coronary or congenital disease [39] or
predominantly confined to heart muscle like in inherited or
acquired cardiomyopathies. Transthoracic echocardiography
is used as a first line imaging tool for identifying and descrip-
tion of the phenotype. It typically shows global left or
biventricular hypokinesis with or without regional wall mo-
tion abnormalities. Ventricular and atrial dilatation, intracardi-
ac thrombi and functional mitral regurgitation due to annular
dilatation might also be noted. Doppler parameters can assist
in quantifying valvular abnormalities and the severity of dia-
stolic dysfunction [40]. CMR is superior to echocardiography,
it provides accurate assessment of ventricular volumes, wall
thickness and contractile function, as well as tissue character-
isation [41]. Typical patterns of subendocardial, mesocardial
and subepicardial LGE distribution reflect underlying patho-
physiological processes and reveal aetiology with such a level
of confidence that in many cases myocardial biopsy may be
omitted. CMR relaxometry can indicate myocardial necrosis,
scarring, focal and diffuse replacement interstitial fibrosis,
whereas high signal T2 intensity or increased T2 mapping
values suggest myocardial oedema and inflammation [42].
The 4D-Flow technology allows the assessment of flow-
based forces and their altered haemodynamic effects on the
myocardial wall with a potential to become a maker of pro-
gressive adverse cardiac remodelling [43].
Post-ischemic heart failure
Reflecting perfusion contraction matching and mismatching,
ischaemic heart failure (IHF) consists of a spectrum of patho-
physiological states, from early remodelling characterised by
wall thinning and dilatation to irreversible late remodelling
resulting from myocardial fibrosis and scar [44].
Echocardiography with three-dimensional (3D) acquisition,
in addition to stress and contrast echocardiography enables a
comprehensive view of myocardial function, contractile re-
serve and perfusion. Resting two-dimensional echocardio-
grams are the first step in IHF patients and allow us to quantify
LV function and assess the presence of resting regional wall
motion abnormalities, which are the hallmark of disease [45].
Use of myocardial deformation imaging enables detection of
abnormal myocardial contractility in earlier stages of the
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disease, but it is of limited value in defining aetiology or
predicting viability of myocardium [46]. CMR on the other
hand has a saying inmyocardial viability by identifying partial
or full thickness myocardial infarction based on the pattern of
LGE distribution - subendocardial or transmural, respectively.
Moreover, CMR showed to be superior to echocardiography
in discriminating between hibernating and necrotic myocardi-
um independently from wall thickness [47]. Akinetic seg-
ments with > 50% transmural LGE are considered non-
viable (necrotic), whereas akinetic segments with no LGE
have an approximately 80% likelihood of functional recovery
[48]. Once the scar transmurality exceeds 50% the likelihood
of functional recovery drops to approximately 8% [49]. The
presence and amount of LGE is prognostically important and
associated with major adverse cardiac event (MACE) and car-
diac mortality [50], and it is an independent predictor of all-
cause mortality or cardiac transplantation [51].
Idiopathic dilated cardiomyopathy
Mutations in over 50 genes have been associated with dilated
cardiomyopathy [52]. Multiple failing mechanisms result in
altered force generation and cell death, leading to left ventric-
ular systolic dysfunction and heart failure. Diagnostic criteria
of LV dilatation with reduced function applies to ‘idiopathic’
DCM once secondary causes have been excluded [53, 54].
Echocardiography is the first-line diagnostic tool. Volumes
and EF acquired from 3D echocardiography correlate better
with CMR and their use is recommended when feasible [55].
LVenlargement and alterations in GLS typically precedes LV
dysfunction assessed by 2D classical parameters [56].
Moreover, decreased GLS showed ability to discriminate
gene-positive phenotype-negative individuals from normal
controls, which may permit early institution of therapy for
genetic DCM [57]. Similar findings should be expected from
the feature tracking obtained by CMR. CMR plays a central
role in phenotypic assessment. Approximately 25% of pa-
tients with dilated cardiomyopathy (DCM) will have evidence
of mid-wall fibrosis [58] which is an independent predictor of
mortality and morbidity. DCM patients with mid-wall fibrosis
had a similar outcome to those with ischemic disease [59].
Thus, as with ischemic cardiomyopathy, the presence of
fibrosis/scar is a marker of adverse outcome and worse re-
sponse to device therapy. Similarly, T1 mapping sequences
together with measurement of ECV expansion has proved to
have an additional value over EF in prognostic assessment
(Fig. 1) [60].
Systolic dysfunction in HFpEF and HFrEF
patients
The longitudinal trajectories of LV ejection fraction vary be-
tween the two conditions in a very sensitive way. When ade-
quate follow-up is available, repeat echocardiograms in
HFpEF can detect a maximum of 2–5% fell in EF over 5
years, with a larger fall in the presence of coexisting coronary
artery disease [61, 62]. A similar analysis, conducted over a
follow-up period up to 15 years in HFrEF patients, observed
an inverted U-shaped relation whereby EF indeed increased
over the initial 10 years but slowly declined afterward [63].
Comparable data should be available when looking at systolic
deformation, particularly in the circumferential or radial direc-
tion, either assessed using CMR or echocardiography [64].
Fig. 1 Patterns of late gadolinium enhancement and corresponding cardiac MRI images
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Thus, clear discrepancies in LV systolic performance between
HFpEF vs. HFrEF populations long-term trajectories make
unlikely amechanistic continuum between the two conditions,
which can be represented as distinct HF phenotypes [65].
Diastolic dysfunction in HFpEF and HFrEF
patients
More similarities, than discrepancies, instead, can be detected
when looking at diastolic dysfunction in HFpEF vs. HFrEF
patients. Diastolic dysfunction contributes to exercise intoler-
ance, both in systolic and primary diastolic dysfunction. In
both conditions, in fact, diastolic impairment limits exercise
tolerance before resulting in symptoms at rest [66].
In the absence of mitral stenosis, the two major factors that
determine the early diastolic mitral valve pressure gradient
and the rate of LV filling are the rate of LV relaxation and
the LA pressure at the time of mitral valve opening [67].
With exercise, normally, there is a fall in early diastolic LV
pressure that results in an increased early diastolic pressure
gradient, without an increase in LA pressure to abnormal
levels. This increment in gradient, obtained with no increment
in LA cavity pressure, produces an improvement in the rate of
early diastolic LV filling [68]. When HF ensues, however,
peak early diastolic filling rate and diastolic mitral valve pres-
sure gradient increase as during normal exercise but with a
different mechanism. Relaxation, in fact, which is slower at
rest in HF, is further slowed down during exercise, while early
diastolic LV pressure increases [69]. Thus, the increased rate
of early diastolic LV filling and the mitral valve pressure gra-
dient in HF result from an abnormal increase in LA pressure.
Non-invasive methods to identify LV and LA pressure have
recently been discussed and even the traditional echo param-
eters considered markers of elevated LV filling pressure such
as reduced mitral deceleration time (DT) and isovolumic re-
laxation time (IVRT) blunted Awave and high E/e′ ratio have
been debated. In theory, the occurrence of the above-
mentioned picture is typical of a restrictive pattern and along
with increased LAvolume and increased pulmonary pressure,
reflects high filling pressure in either HFrEF and HFpEF [70].
However, only a few studies compared Doppler and CMR
parameters with direct haemodynamic measurement. Most
of these studies analysed only E/e′ ratio in relation to wedge
pressure, but a complete measurement of left chambers pres-
sure is lacking [71, 72]. Therefore, correlation between E/e′
ratio and LVEDP in a recent metanalysis appears modest and
patients with atrial fibrillation (AF) were excluded [73]. All
these concerns put some doubts and limitation in evaluation of
isolated diastolic dysfunction and consequently in the diagno-
sis of HFpEF. Thus, TDI and PW Doppler parameters may be
integrated with careful analysis of cardiac structure and LV
remodelling. Accordingly, elevated LA pressure leads to LA
dysfunction and remodelling being commonly observed in
both phenotypes. These findings, at a difference from systolic
properties, would suggest a mechanistic continuum, as far as
diastole is concerned, between the two conditions. It must be
recognised, however, that LA remodelling in HFpEF and
HFrEF, has been reported as being slightly different, with
more dilation and systolic dysfunction in HFrEF and with
increased stiffness, pulsatility and predilection for atrial fibril-
lation (AF) in HFpEF [74]. We think that this distinction is
partly artefactual. The extent of LA pulsatility, that is a direct
function of the stiffness of the cavity, may contribute to the
pulsatile major component of right ventricular afterload [75].
Thus, from this perspective, diastolic LA dysfunction can be
seen as an active contributor to symptoms and to disease pro-
gression for both phenotypes.
Novel methods combining echo and CMR
analysis for best risk prediction in atrial
fibrillation patients
Diastolic dysfunction is a dominant feature in many HF pa-
tients. LV diastolic dysfunction causes LA dilatation, which
can lead to AF [76]. Despite of being advance in management
and treatment, AF remains a source of considerable morbidity
and mortality worldwide. For the patients in sinus rhythm LV,
filling pressures and diastolic function grade can be deter-
mined reliably by a few simple echocardiographic or CMR
parameters with a high feasibility [77]. However, for the pa-
tients in AF regardless whether AF is a reason or consequence,
assessment of diastolic function is challenging. Assessment in
this condition in limited by cycle length variability, absence on
an organised atrial activity and frequent occurrence of atrial
enlargement regardless of filling pressures [78]. Recently,
some new indexes using speckle tracking echocardiography
have shown promising results showing the association be-
tween LV systolic and diastolic strain, LA strain and LV dia-
stolic function in AF patients [79]. Indexes potentially capable
of describing the delicate atrio-ventricular relation should con-
vey the strongest pathophysiological information and be less
influenced by R-R variations, if they can be comprehensively
acquired in 1 single beat.
Recently, in characterising the governing role of the four-
chamber (near) constant-volume pump physiology, wherein
the atrial and ventricular volumes simultaneously reciprocate
throughout the cardiac cycle, CMR has elucidated and
characterised LA and LV phasic function, thereby quantifying
the conduit contribution to ventricular filling as the integral of
net, diastolic, instantaneous difference between synchronised
atrial and ventricular volume curves [80]. Because cardiac
CMR availability is limited, 3D echocardiography can be
employed to acquire complete and simultaneous LA and LV
full-volume datasets to characterise the volume of both left-
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sided cardiac chambers at each time point during the cardiac
cycle in order to quantify conduit [81] (Fig. 2).
Using single-beat simultaneous left atrial and ventricular
full-volume 3D dataset, it was demonstrated that the atrial
conduit contribution to ventricular filling has a direct relation-
ship with the degree of underlying ventricular diastolic impair-
ment in HF patients [82]. More recently, it was shown that
conduit quantitation is also able to predict 1-month AF
recurrence in a population of persistent AF patients imaged
immediately after and/or before electrical cardioversion [83].
These findings support the concept that conduit (independent-
ly of the imaging technique used to quantify it), reflects intrin-
sic atrial pathology that cannot be sufficiently explained by
ventricular pathology only and thus it could be proposed as a
clinically effective tool for exploring the link between AF and
diastolic dysfunction, in excess of ventricular derangement.
Fig. 2 Left atrial conduit volume quantification by 3D echocardiography.
Left, single-beat simultaneous left atrial (LA)–left ventricular (LV) pyra-
midal 3D echocardiographic full-volume dataset as obtained from the
apex in a given patient, using the 4V transducer during held respiration
(frame rate > 16.5/s).The volume data are displayed in real time, three
apical views and one cross-sectional slice, with optional volume-
rendering techniques for visualisation of valves and structures. Right,
conduit volume is quantified according to the formula: (LV at time (t)
minus LVminimum) minus (LAmaximal minus LA at time (t)), integrat-
ing volume data from minimum LV volume to the beginning of LA
contraction (as identified from simultaneously acquired ECG signal)
and expressed as percent of LV stroke volume
Fig. 3 Assessment of myocardial
fibrosis by CMR. Basal, mid- and
apical slices showing native T1
(top line) and ECV (bottom line)
colour maps used for quantitative
assessment of cardiac fibrosis
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In addition to LA and LV volume curves, CMR can pro-
vide further information on myocardial tissue characteristics.
Myocardial fibrosis have been implicated in the pathophysi-
ology of HFpEF by promoting adverse ventricular remodel-
ling, increasing myocardial stiffness, and in turn, causing dia-
stolic dysfunction [84]. Diffuse interstitial fibrosis, a precursor
for replacement fibrosis, is not detected by LGE but correlates
with T1 mapping, which allows a quantitative assessment of
diffuse cardiac fibrosis and estimations of the extracellular
matrix volume (ECV) (Fig. 3) [85, 86]. There has been accu-
mulating evidence that increased T1 times and ECVare relat-
ed to clinical outcomes [87–89] and have potential for risk
assessment in patients with AF.
Conclusion
Heart failure is disease with large phenotypic variations in
morphology, function and natural history. Such a heterogene-
ity in presentation is perhaps a reason why despite different
clustering approaches, many interventions in clinical trials
have not shown efficacy. Cardiac imaging provides diverse
insights, but the ability to distinguish between overlapping
phenotypes remains a challenging proposition. The evaluation
of diastolic function by echocardiography and CMRwith their
traditional and novel techniques deserves specific analysis and
a comparison with haemodynamic measurement before to be
universally accepted. Diastolic function parameters derived by
CMRmay be applied in routine clinical care andmatched with
more feasible echo analysis in order to increase our awareness
in the HFpEF mechanisms and reduces the current diagnostic
gap. New parameters studying both radial and circumferential
relaxation together with identification of extracellular collagen
volume could facilitate the diagnosis and will play a central
role in the identification of underlying pathophysiological
mechanisms. Comparative imaging trials should be encour-
aged in order to discern which technique(s) alone, or in com-
bination, could provide additional prognostic value.
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